We are developing a robust pipeline of first-in-class or best-in-class therapeutic antibodies that mobilize the human immune system to combat cancer, autoimmune disorders and other unmet medical needs around the world. We are actively progressing our own internal projects, while also establishing multiple partnerships with leading pharmaceutical and biotechnology companies, as well as academic institutions. Our current focus is on discovering and advancing novel therapeutic antibodies to target regulatory T cells and Myeloid-derived suppressor cells.
We apply our proprietary single-B-cell functional antibody discovery CelliGO™ platform to develop best-in-class therapeutics. Key platform advantages include:
Open innovation strategies encourage external collaborations to help allocate resources more efficiently, improve product development and accelerate commercialization.
We believe in open innovation and continue to establish strategic partnerships and joint ventures with leading pharmaceutical and biotechnology companies, as well as academic institutions to better address unmet medical needs around the world. We are currently working together with many of the world’s top immunologists and oncologists to better understand the biological targets and the patient needs. All of our collaborations are streamlined for speed and driven by our scientific strategy.
Read our article in Drug Discovery Today for more information
Our high scientific standards have been validated in numerous peer-reviewed publications and conference presentations.